Last reviewed · How we verify

Cyclosporine NOVA22007 0.05%

Santen SAS · Phase 2 active Small molecule

Cyclosporine NOVA22007 0.05% is a Calcineurin inhibitor Small molecule drug developed by Santen SAS. It is currently in Phase 2 development for Treatment of uveitis.

Cyclosporine is an immunosuppressant that inhibits calcineurin, thereby reducing T-cell activation.

Cyclosporine is an immunosuppressant that inhibits calcineurin, thereby reducing T-cell activation. Used for Treatment of uveitis.

At a glance

Generic nameCyclosporine NOVA22007 0.05%
SponsorSanten SAS
Drug classCalcineurin inhibitor
TargetCalcineurin
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 2

Mechanism of action

Cyclosporine works by binding to cyclophilin, which inhibits calcineurin's phosphatase activity. This prevents the dephosphorylation of NFAT, a transcription factor that regulates T-cell activation. As a result, T-cell activation is reduced, and the immune response is suppressed.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cyclosporine NOVA22007 0.05%

What is Cyclosporine NOVA22007 0.05%?

Cyclosporine NOVA22007 0.05% is a Calcineurin inhibitor drug developed by Santen SAS, indicated for Treatment of uveitis.

How does Cyclosporine NOVA22007 0.05% work?

Cyclosporine is an immunosuppressant that inhibits calcineurin, thereby reducing T-cell activation.

What is Cyclosporine NOVA22007 0.05% used for?

Cyclosporine NOVA22007 0.05% is indicated for Treatment of uveitis.

Who makes Cyclosporine NOVA22007 0.05%?

Cyclosporine NOVA22007 0.05% is developed by Santen SAS (see full Santen SAS pipeline at /company/santen-sas).

What drug class is Cyclosporine NOVA22007 0.05% in?

Cyclosporine NOVA22007 0.05% belongs to the Calcineurin inhibitor class. See all Calcineurin inhibitor drugs at /class/calcineurin-inhibitor.

What development phase is Cyclosporine NOVA22007 0.05% in?

Cyclosporine NOVA22007 0.05% is in Phase 2.

What are the side effects of Cyclosporine NOVA22007 0.05%?

Common side effects of Cyclosporine NOVA22007 0.05% include Hypertension, Nephrotoxicity, Diabetes mellitus, Hirsutism, Gingival hyperplasia.

What does Cyclosporine NOVA22007 0.05% target?

Cyclosporine NOVA22007 0.05% targets Calcineurin and is a Calcineurin inhibitor.

Related